EQ 300/500

Product Overview

EQ 300 and EQ 500 by Zyvex Pharmaceuticals are injectable formulations containing Boldenone Undecylenate at concentrations of 300 mg/ml and 500 mg/ml, respectively, supplied in 10 ml vials. Boldenone is a synthetic anabolic-androgenic steroid (AAS) structurally related to testosterone, while the undecylenate ester provides prolonged release following intramuscular administration.

Boldenone Undecylenate is widely recognized by the historical veterinary trade name Equipoise and the abbreviation EQ. Unlike testosterone or Nandrolone, Boldenone does not have an established contemporary therapeutic role in routine human medicine and is primarily associated with veterinary use and non-medical bodybuilding.

Within physique and strength communities, Boldenone is commonly associated with gradual lean-mass development, appetite changes, endurance-oriented effects, and increases in red blood cell production. These properties do not establish it as a safe or approved human performance medication. The stated concentrations of 300 mg/ml and 500 mg/ml indicate product strength only and should not be interpreted as recommended individual doses.

Product Class

• Injectable anabolic-androgenic steroid (AAS)
• Testosterone-derived androgen
• Long-acting undecylenate ester
• Androgen receptor agonist
• Veterinary-origin anabolic compound

Indications

Clinical and Veterinary Context

Boldenone Undecylenate has been used primarily in veterinary medicine as an anabolic agent, particularly to support weight gain, appetite, and recovery in selected animals. It should not be assumed to have an approved therapeutic indication for human muscle wasting, hypogonadism, anemia, osteoporosis, or athletic recovery simply because it shares structural similarities with testosterone.

Human medical use is not established in contemporary clinical practice, and safer, regulated alternatives exist for conditions such as testosterone deficiency, anemia, and clinically significant loss of lean tissue.

Performance Context

Within bodybuilding and strength-training communities, Equipoise is commonly discussed for:

• Gradual lean-mass development
• Strength progression
• Body recomposition
• Off-season anabolic programs
• Appetite stimulation
• Endurance-oriented training
• Increased vascularity

These uses are non-medical and are not supported by an approved human therapeutic indication. Boldenone is also prohibited in drug-tested competitive sport.

Mechanism of Action

After intramuscular administration, Boldenone Undecylenate is released gradually from the injection depot and hydrolyzed to active Boldenone. Boldenone binds to intracellular androgen receptors and modifies transcription of androgen-responsive genes.

Androgen receptor activation may influence:

• Muscle protein synthesis
• Nitrogen retention
• Lean-tissue development
• Bone metabolism
• Erythropoiesis
• Recovery from catabolic stress

Boldenone differs from testosterone through an additional double bond in its steroid structure. This modification alters its anabolic, androgenic, and estrogenic properties while preserving substantial androgen receptor activity.

Boldenone can undergo aromatization to estrogen, although generally to a lesser extent than testosterone. It can therefore still contribute to estrogen-related effects depending on exposure and individual metabolism.

Potential Benefits

Experimental and performance-oriented discussions commonly associate Boldenone with:

• Gradual increases in lean body mass
• Improved nitrogen retention
• Strength-related effects
• Increased red blood cell production
• Potential improvement in appetite
• Long-duration anabolic activity
• Relatively lower estrogenic conversion than testosterone

These effects should not be confused with proven medical benefit in humans. In particular, increased erythropoiesis may raise hematocrit and blood viscosity rather than represent a universally desirable effect.

Synergy & Stacking

Equipoise is frequently discussed alongside other anabolic steroids because of its long duration and relatively gradual anabolic profile. These combinations are not standardized medical treatments and can produce additive endocrine, cardiovascular, hematological, and reproductive effects.

• Testosterone: Frequently discussed as a foundational androgen because Boldenone suppresses endogenous testosterone production.
• Deca-Durabolin (Nandrolone Decanoate): Sometimes compared or combined in mass-oriented performance contexts.
• Anavar (Oxandrolone): Occasionally associated with lean-mass or physique-oriented phases.
• Masteron (Drostanolone): Sometimes discussed in lower-estrogen physique combinations.
• Growth Hormone: Commonly referenced because GH/IGF-1 signaling differs from direct androgen receptor activation.

Aromatase inhibitors such as Anastrozole or Exemestane are also mentioned in bodybuilding discussions because Boldenone can aromatize. However, an aromatase inhibitor should not automatically accompany Boldenone exposure. Estrogen management should be based on clinical findings and hormone testing rather than on a predetermined steroid stack.

HRT/TRT Application

Boldenone Undecylenate is not an established Testosterone Replacement Therapy (TRT) medication. Testosterone remains the physiological replacement hormone for men with appropriately diagnosed hypogonadism.

Although Boldenone activates androgen receptors, it does not reproduce the complete endocrine physiology of testosterone. Its estrogenic conversion, metabolism, long ester duration, and effects on blood parameters differ substantially from approved testosterone preparations.

Exogenous Boldenone also suppresses hypothalamic-pituitary-gonadal signaling. This can reduce luteinizing hormone (LH), follicle-stimulating hormone (FSH), endogenous testosterone production, intratesticular testosterone, and spermatogenesis.

For these reasons, EQ should not be considered an alternative to evidence-based TRT in men with testosterone deficiency.

Dosing and Use

There is no regulator-approved human bodybuilding dose or cycle for Boldenone Undecylenate. The compound lacks an established human therapeutic indication, and performance regimens circulated online should not be treated as medically validated dosing protocols.

The two formulations differ in concentration:

• EQ 300: 300 mg of Boldenone Undecylenate per ml
• EQ 500: 500 mg of Boldenone Undecylenate per ml

A 10 ml vial therefore contains substantially different total amounts of active substance depending on the formulation. Higher concentration should not be interpreted as superior effectiveness or as a recommended administration amount.

Boldenone Undecylenate is a long-acting depot ester. Once injected, active exposure can persist for an extended period, meaning that excessive exposure cannot be rapidly reversed simply by stopping future injections.

Because there is no approved human dosing framework, there is likewise no medically established loading phase, maintenance schedule, cycle length, or post-cycle protocol for EQ 300 or EQ 500.

Female Use

Boldenone is an androgenic anabolic steroid and can produce significant virilization in women.

Potential androgenic effects include:

• Voice deepening
• Increased facial and body hair
• Acne and oily skin
• Menstrual irregularities
• Changes in libido
• Clitoral enlargement
• Androgen-related scalp hair loss

Some virilizing changes may be irreversible. The prolonged release of the undecylenate ester adds an additional concern because exposure continues after administration, limiting the ability to rapidly discontinue the pharmacological effect.

Boldenone should not be used during pregnancy because androgen exposure may interfere with fetal sexual development.

Comparative Analysis

EQ 300 vs EQ 500

• EQ 300: Contains 300 mg/ml of Boldenone Undecylenate.
• EQ 500: Contains 500 mg/ml of Boldenone Undecylenate.
• Both contain the same active steroid and the same undecylenate ester.
• The primary difference is concentration, not mechanism of action.
• 500 mg/ml should not be interpreted as an appropriate single dose.

Equipoise vs Testosterone Enanthate

• Equipoise: Contains Boldenone, a synthetic testosterone-derived anabolic steroid.
• Testosterone Enanthate: Delivers testosterone, the principal endogenous male androgen.
• Testosterone has established TRT applications; Boldenone does not.
• Boldenone generally aromatizes less than testosterone but can still produce estrogenic effects.

Equipoise vs Deca-Durabolin

• Equipoise: Boldenone Undecylenate, a testosterone-derived anabolic steroid.
• Deca: Nandrolone Decanoate, a 19-nor anabolic steroid.
• Nandrolone has greater progestogenic relevance, while Boldenone is more frequently associated with pronounced increases in erythropoiesis.

Equipoise vs Primobolan

• Equipoise: Long-acting Boldenone ester capable of some aromatization.
• Primobolan: Methenolone, a DHT-derived non-aromatizing anabolic steroid.
• The compounds differ substantially in estrogenic activity, metabolism, and androgenic profile.

Equipoise vs Trenbolone

• Equipoise: Moderate anabolic-androgenic compound with a long ester and some aromatization.
• Trenbolone: Potent 19-nor anabolic steroid with markedly different androgenic and progestogenic properties.
• Neither has an established role as conventional human TRT.

Conclusion

EQ 300 and EQ 500 by Zyvex Pharmaceuticals are 10 ml injectable formulations containing Boldenone Undecylenate at 300 mg/ml or 500 mg/ml. Boldenone is a long-acting testosterone-derived anabolic-androgenic steroid widely recognized under the names Equipoise and EQ.

Its androgen receptor activity, prolonged ester, effects on lean tissue, and tendency to stimulate erythropoiesis explain its longstanding popularity in bodybuilding. However, Boldenone does not have an established contemporary human therapeutic indication and should not be characterized as a TRT medication. The distinction between EQ 300 and EQ 500 is concentration only, and neither strength represents a recommended individual dose.